Heartland Bank & Trust Co Has $649,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Heartland Bank & Trust Co decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 51.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,486 shares of the company’s stock after selling 4,672 shares during the period. Heartland Bank & Trust Co’s holdings in Johnson & Johnson were worth $649,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Quarry LP bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at $49,000. Ashburton Jersey Ltd bought a new position in Johnson & Johnson in the second quarter valued at about $8,771,000. Mattson Financial Services LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth about $3,407,000. First Financial Bank Trust Division increased its stake in shares of Johnson & Johnson by 1.3% in the third quarter. First Financial Bank Trust Division now owns 62,803 shares of the company’s stock valued at $10,178,000 after buying an additional 779 shares during the period. Finally, Davis Capital Management raised its holdings in Johnson & Johnson by 4.4% in the 3rd quarter. Davis Capital Management now owns 10,432 shares of the company’s stock valued at $1,691,000 after buying an additional 441 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 1.1 %

Shares of Johnson & Johnson stock opened at $152.78 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a 50 day moving average price of $147.73 and a two-hundred day moving average price of $156.10. The stock has a market capitalization of $367.82 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.29 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on JNJ. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Citigroup cut their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Barclays lifted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Finally, Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $170.44.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.